Showing results (91-100 of 150) with videos related to
Sort By:
Pageof 15
Molecular Cancer Therapeutics|May 1, 2008
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cellsEllen Weisberg, Renee D Wright, Douglas W McMillin, et al.Cancer Research|June 28, 2014
High-throughput time-resolved FRET reveals Akt/PKB activation as a poor prognostic marker in breast cancerSelvaraju Veeriah, Pierre Leboucher, Julien de Naurois, et al.Cancers|April 13, 2024
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple MyelomaBasudev Chowdhury, Swati Garg, Wei Ni, et al.Emergency Medicine Australasia : EMA|March 23, 2023
Emergency examination authorities in Queensland, AustraliaAlan R Clough, Angela Evans, Veronica Graham, et al.British Journal of Cancer|February 5, 2020
Inhibition of the deubiquitinase USP10 induces degradation of SYKJing Yang, Chengcheng Meng, Ellen Weisberg, et al.The New England Journal of Medicine|October 6, 2006
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletionAlan List, Gordon Dewald, John Bennett, et al.Plos One|February 26, 2013
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cellsEllen Weisberg, Qingsong Liu, Xin Zhang, et al.Journal of Cellular and Molecular Medicine|January 23, 2020
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemiaEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.Blood|July 22, 2006
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsMark Levis, Patrick Brown, B Douglas Smith, et al.NEJM Evidence|February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell LeukemiaJae H Park, Sean Devlin, Benjamin H Durham, et al.Pageof 15